Spots Global Cancer Trial Database for Study of AK112 in the Treatment of Advanced Gynecological Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of AK112 in the Treatment of Advanced Gynecological Tumors
Official Title: Phase II Study of AK112 (Anti-PD-1 and VEGF Bi-specific Antibody) in the Treatment of Advanced Gynecological Carcinoma
Study ID: NCT04870177
Interventions
Study Description
Brief Summary: A phase II study to evaluate the efficacy and safety of AK112 in subjects with advanced gynecological tumors.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Qilu Hospital of Shandong University, Qilu, Shandong, China
Chongqing University Cancer Hospital, Chongqing, , China
Contact Details
Name: Beihua Kong, MD
Affiliation: Qilu Hospital of Shandong University
Role: STUDY_CHAIR
Name: Qi Zhou, MD
Affiliation: Chongqing University Cancer Hospital
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
